Update on Transition Clinical Trial: ELND005

Transition Therapeutics Inc. (Elan) announced the results of a clinical study of drug candidate ELND005 in young adults with Down syndrome. The study focuses on neuropsychiatric symptoms associated with Alzheimer’s disease and cognition in people with Ds.

In our September 2013 Newsflash, LuMind Foundation’s Chief Scientific Officer Dr. Harpold explained the ELND005 study. Essentially, ELND005 is a molecule that may hold the potential to improve cognition in Ds, in part, by reducing aggregation of beta-amyloid, which is a product of the amyloid precursor protein (APP) encoded by a gene on chromosome 21 — thus preventing the intraneuronal buildup of beta-amyloid plaques that most people with Ds develop by their 40s associated with Alzheimer’s disease.

LuMind-supported research has previously shown reducing the levels of APP and/or certain of the APP-derived beta-amyloid products overcome specific cognitive and neurodegenerative Alzheimer’s disease-related effects in mouse models of Down syndrome.

LuMind has also been working with Transition Therapeutics to supported clinical trial participant recruitment. Your donations and support helped advance this clinical trial!

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s